We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.14 | 2.10 | 2.18 | 2.20 | 2.19 | 2.19 | 604,698 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/5/2020 12:42 | Imm has no debt. Littlepup filtered | wigwammer | |
14/5/2020 11:59 | Response from Immunology Institute of the Icahn School of Medicine, Mount Sinai 4 days ago to Emory University research findings ... Referring to the significance of their findings ... Using a specialized flow cytometry panel for B cell analysis, the authors provide a description of the B cell landscape in COVID-19 patients. Understanding the role of potentially pathogenic B cell modules could be crucial for designing immuno-modulatory therapies that target pro-inflammatory or potentially autoimmune phenotypes seen with SARS-CoV-2 infections. Immupharma - whole raison d’etre is immuno-modulatory therapies. Maybe Nobby can duck out from bickering long enough to provide his detailed assessment of this Emory study and Mount Sinai review? | borromini1 | |
14/5/2020 11:20 | The bounce back after the GAP is on Buys are now pouring in | master rsi | |
14/5/2020 11:12 | Dave. Avion, the cnrs and the fda know what they're talking about - and the day before the ph3 results are read out, that is the opinion the market will be pricing in. Not the opinion of some self appointed guru on the ADVFN chat board. ImmuPharma is now largely funded to get to that result and I suspect we will see an exponential rerating prior to readout which will offer multiple profit taking stages. Atb | wigwammer | |
14/5/2020 10:56 | Responses to US Emory University Research article released on 3 May include Alex Woodruff ... Important new research out of @EmoryUniversity. Critically ill patients with #COVID19 show lupus-like b-cell activation. This may help us understand the large racial disparities in death numbers and guide treatment for those vulnerable! Somebody tell Matt and Boris! | borromini1 | |
14/5/2020 10:51 | I know you guys hate the fact that I know what I am talking about. Twenty eight years in the Pharma industry working at all stages of drug development in rheumatology and gastroenterology has given me exactly the correct sort of experience to be able to assess Lupuzor and other drugs! So sorry about that.... | nobbygnome | |
14/5/2020 10:43 | Lol. Let him talk to himself for a while :) | wigwammer | |
14/5/2020 10:37 | Point Nobby.. About today's news ? Don't you think Tim just ramped up this share as usual. To ride this wave I bought today to trade it out but when I read RNS i laughed like anything. Every other Pharma company coming up with COVID RNS it seems. | idontflykathyy | |
14/5/2020 10:33 | As we have discussed before the FDA really are not that concerned about efficacy; safety is the key issue for them. If you can convince them you have a half decent plan, they will let you go ahead. It is no skin off their nose if the drug fails and indeed they still collect all the fees involved! I have been present in those meetings myself so know what I am talking about.... | nobbygnome | |
14/5/2020 10:26 | Bought again at 18P cmon IMM - I'm here for a day or two trade. Dont disappoint me lol | idontflykathyy | |
14/5/2020 10:25 | Opening at 16.50p UT this morning has created a GAP it has now been filled, some good chance of moving higher again. | master rsi | |
14/5/2020 10:10 | "IMHO"... exactly...in nob's opinion. But not in the opinion of avion, the cnrs, or the fda. | wigwammer | |
14/5/2020 10:07 | >> wiggy Still virtually no chance of it working IMHO! Avion are like lambs to the slaughter.... | nobbygnome | |
14/5/2020 10:04 | Cmon IMM reach to 25P and I exit.. What a shame as according to few LSE member this is 40P share lol | idontflykathyy | |
14/5/2020 10:03 | ie the people that count. | wigwammer | |
14/5/2020 10:03 | Lupuzor is probably going back into phase 3. This suggests that avion, the cnrs, the fda, and all the other people required to get it into phase 3 don't agree with you. | wigwammer | |
14/5/2020 10:00 | Lupuzor working in any indication would be more of a miracle.... | nobbygnome | |
14/5/2020 09:56 | I'm interested in a miracle, nob. That your good friend Kathy from Malta has suddenly lost all trace of spanglish. Alleluia! :) | wigwammer | |
14/5/2020 09:52 | A super scientist with flawed alter egos who can save the Dow - I'm on the blower to Marvel. | daveboy1 | |
14/5/2020 09:45 | Why only stop at 25% ? Guys we need to pump more | idontflykathyy | |
14/5/2020 09:43 | Very strange question. Isn't talking about IMM on an IMM thread slightly more relevant.... | nobbygnome | |
14/5/2020 09:39 | Never mind that. Did you say Kathy was from Malta? | wigwammer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions